Wolfgang Füreder

Medical University of Vienna — Austria

Immunology and Microbiology · Life Sciences

21h-index1.9kcitations54works1.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Complement system in diseases(21), Mast cells and histamine(19), Coagulation, Bradykinin, Polyphosphates, and Angioedema(15), Renal Diseases and Glomerulopathies(12), Acute Myeloid Leukemia Research(6)

Publications54 total

Ravulizumab exposure in early pregnancy
Annals of Hematology·2025Open Access
Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events – case report
Hematology·2025Open Access
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria
Annals of Hematology·2025· 7 citedOpen Access
Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy– a report of two cases
Annals of Hematology·2024· 1 citedOpen Access
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab
Leukemia & lymphoma/Leukemia and lymphoma·2024
Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)
Wiener klinische Wochenschrift·2024· 2 citedOpen Access
Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
Annals of Hematology·2024Open Access
Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up
Blood·2023· 1 cited
Ravulizumab Provides Durable Control of Intravascular Hemolysis and Improves Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Follow-up of Study 301 and Comparisons with Patients of the International PNH Registry
Blood·2023· 5 cited
PCR187 Patient and Physician Satisfaction of Treatment with Eculizumab or Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: Results from a Real-World Disease-Specific Programme
Value in Health·2023
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up
Advances in Therapy·2022· 22 citedOpen Access
P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS
HemaSphere·2022· 4 citedOpen Access
P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
HemaSphere·2022· 6 citedOpen Access
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network
Annals of Hematology·2020· 11 cited
Switching From High‐Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
HemaSphere·2020· 5 citedOpen Access
Results from a Phase 3, Multicenter, Noninferiority Study of Ravulizumab (ALXN1210) versus Eculizumab (ECU) in Adult Patients (pts) with Paroxysmal Nocturnal Hemoglubinuria (PNH) Naive to Complement Inhibitors (CI)
Hämostaseologie·2019
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Blood·2018· 380 citedOpen Access
Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
Haematologica·2018· 75 citedOpen Access
Major response of PNH to an AML chemotherapy protocol
Annals of Hematology·2018· 2 cited
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML
Leukemia Research·2017· 66 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Peter Valent(33), Wolfgang R. Sperr(23), Klaus Lechner(22), Hermine Agis(12), Martin Willheim(10), Hans Bankl(10), Mehrdad Baghestanian(8), Christian Sillaber(5), Dorian Bevec(5), Michael Müller(5), Klaus Geißler(5), Ilse Schwarzinger(5), Sandra Fátima Menosi Gualandro(4), Hubert Schrezenmeier(4), Uwe‐G. Maier(4), Hans P. Kiener(4), Otto Scheiner(4), Masayo Ogawa(4), Austin Kulasekararaj(4), Jong Wook Lee(3)